Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multicenter study of PRL3-zumab in solid tumors
CTR20211180Phase 2Active
- Sponsor
- Intra-ImmuSG
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PRL3-zumab in Nonhematologic neoplasms, sponsored by Intra-ImmuSG. Started Sep 2021; status: active.
02
Drugs
PRL3-zumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20211180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211180.